Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 691 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corticosteroid Clear all

Conditions: Allergy
Interventions: Fluticasone, Fluticason; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Asthma
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 21
States / cities: Bakersfield, California • Newark, Delaware • Kissimmee, Florida + 17 more

Conditions: Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions: ADCT-701; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma, Bone Density, Low, Oral Steroid-Dependent Asthma (Disorder)
Interventions: CT Scan, DXA Scan, Steroid Intake Questionnaire; Radiation · Other
Lead sponsor: University of Iowa; Other
Eligibility: 25 Years to 45 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions: Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more

Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions: Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more

Conditions: Atopic Dermatitis
Interventions: MOR106, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Fountain Valley, California • Huntington Beach, California • Los Angeles, California + 11 more

Conditions: Respiratory Distress Syndrome, Intraventricular Hemorrhage, Neonatal Mortality
Interventions: Betamethasone(Celestone soluspan) and Dexamethasone; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Irrigation head position; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Nonresectable Adrenocortical Carcinoma
Interventions: Iressa (ZD1839); Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 4
States / cities: Louisville, Kentucky • Boston, Massachusetts • Lebanon, New Hampshire + 1 more

Conditions: Kidney Transplant
Interventions: sirolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 18 more

Conditions: Cushing's Syndrome
Interventions: Cushing's syndrome confirmation; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Escondido, California • Hollywood, Florida • San Antonio, Texas

Conditions: Ulcerative Colitis Acute
Interventions: Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Dystrophinopathy, Duchenne Muscular Dystrophy, Becker's Muscular Dystrophy
Interventions: L-arginine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 11 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Kingwood, Texas • Plano, Texas

Conditions: Uveitis, Intermediate, Uveitis, Posterior
Interventions: Dexamethasone pellet; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions: Ivonescimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Graft vs Host Disease
Interventions: Belumosudil (KD025); Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Duarte, California • Minneapolis, Minnesota • Cincinnati, Ohio + 3 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 174
States / cities: Birmingham, Alabama • Hoover, Alabama • Gilbert, Arizona + 146 more

Conditions: Asthma
Interventions: Xolair; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: COVID, Pneumonia, Viral
Interventions: Methylprednisolone; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Coronavirus
Interventions: Dexamethasone Oral; Drug
Lead sponsor: Aetion, Inc.; Other
Eligibility: Not listed
Enrollment: 14,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Knee
Interventions: corticosteroid solution with lidocaine containing parabens., corticosteroid solution with lidocaine containing no paraben; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 19 Years to 89 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Allergic Conjunctivitis
Interventions: hydrocortisone ophthalmic ointment 0.5%, placebo; Drug
Lead sponsor: Koffler Vision Group; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*

Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"

3D Printing to Improve Nasal Irrigation Outcome

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

Study of the Effectiveness of Ozurdex for the Control of Uveitis

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy

Early Short Course Corticosteroids in COVID-19

Dexamethasone and COVID-19 Inpatient Mortality

Parabens Flocculation on the Anti Inflammatory Effects of Corticosteroid Injections for Total Knee Arthroplasty

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis